CD274 and melanoma: In particular, immune checkpoint blockade with antibodies that block CTLA-4, PD-1 or PD-L1 have resulted in durable clinical responses in patients with advanced melanoma, lung, kidney, bladder, and colorectal cancer, but both primary and acquired resistance occur in the majority of patients (1–5, 11).